Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on February 2, 2015, covering events occurring on February 1, 2015. The filing primarily addresses the appointment of two new executive officers and the associated employment and equity agreements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
The material changes reported in this filing are the appointments of two senior executives effective February 1, 2015:
- Andrew R. Boll was appointed Chief Financial Officer (CFO), having previously served as Vice President of Accounting and Financial Reporting since February 2012.
- John P. Saharek was appointed Chief Commercial Officer (CCO), having previously served as Vice President of Commercialization, Ophthalmology since November 2012.
Compensation, Equity, and Management Commentary
Management entered into new employment agreements and granted equity awards to the new officers:
Andrew R. Boll (CFO)
- Base Salary: $200,000 annually.
- Bonus: Target of 50% of base salary (minimum 20%).
- Equity Awards:
- Up to 157,500 performance-based restricted stock units (vesting based on stock price targets over three years).
- Up to 30,000 restricted stock units (vesting on the third anniversary).
- Severance: Six months of base salary upon Qualifying Termination; immediate vesting of equity upon Qualifying Termination within 12 months of a change of control.
John P. Saharek (CCO)
- Base Salary: $220,000 annually.
- Bonus: Target of 50% of base salary.
- Equity Awards:
- Up to 90,000 stock options (exercise price $7.37, vesting quarterly over three years).
- Up to 30,000 restricted stock units (vesting on the third anniversary).
- Severance: Six months of base salary upon Qualifying Termination; 12 months of base salary and immediate equity vesting upon Qualifying Termination within 12 months of a change of control.
Both officers also received standard indemnification agreements.
Investor Verification Checklist
- Verify the company name is Imprimis Pharmaceuticals, Inc. (the input metadata incorrectly listed "Harrow, Inc.").
- Review the full text of the employment agreements (Exhibits 10.1 and 10.3) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the vesting conditions for the 157,500 performance-based RSUs granted to the CFO, as these are tied to specific stock price targets.
- Check the stock option exercise price of $7.37 for the CCO against the current market price to assess dilution potential.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these appointments.